Jordyn Sava is an assistant editor for Targeted Oncology.
Pyrotinib/Capecitabine Shows Activity in HER2-Positive Breast Cancer with Brain Metastases
Pyrotinib combined with apecitabine demonstrated promising activity in patients with HER2-positive breast cancer that have brain metastases, according to findings from the prospective phase 2 PERMEATE study.
Tisagenlecleucel Not Superior to SOC as 2L Treatment for Aggressive B-cell Lymphoma
Significantly longer event-free survival was not demonstrated with tisagenlecleucel in the second-line setting when compared to standard-of-care second-line therapy in patients with refractory or early relapsed aggressive B-cell lymphoma.
FDA Grants Fast Track Designation to 7HP349 for Anti-PD-1 Metastatic Melanoma
Fast track designation has been granted to 7HP349, in combination with a CTLA-4 inhibitor for the treatment of patients with unresectable or metastatic malignant melanoma following treatment failure with a PD-1 inhibitor.
New Agents Advance Treatment Options for Polycythemia Vera
Srdan Verstovsek, MD, discussed the ways in which ropeginterferon and rusfertide can reduce thromboembolic events in polycythemia vera.
Batiraxcept/Cabozantinib Shows Positive Efficacy in Patients With ccRCC
Updated data from the ongoing phase 1b/2 trial of batiraxcept in combination with cabozantinib shows favorable outcomes in patients with clear cell renal cell carcinoma.
Disparities Remain in Pediatric Cancer Despite OS Improvement Over 14 Years
In an interview with Targeted Oncology, David Siegel, MD, explained the many changes seen in pediatric cancer mortality and survival over the past 40 years.
First-Line Nivolumab/Chemotherapy Could Benefit Patients With Gastric/GEJ/Esophageal Cancers
In an interview with Targeted Oncology, Ryan Sugarman, MD, discussed the CheckMate 649 trial and Q-TWiST results to provide a further understanding of survival and quality of life benefit of nivolumab plus chemo versus chemo alone.
New Treatments Emerge for Brain Metastases in HER2+ Metastatic Breast Cancer
Tailored treatment available to patients with HER2-positive metastatic breast cancer based on the presence of active central nervous system disease.
Multifaceted Approach Used for Addressing Cardiotoxicity in Breast Cancer
A team-oriented approach based on guideline-directed therapies should be used by clinicians to address patients experiencing cardiotoxicity as a result of their breast cancer, according Jean-Bernard Durand, MD.
Promising Results Shown With CAR T Cells for MCL and Indolent Lymphoma
In an interview with Targeted Oncology, Lori Leslie discussed the CAR T-cell product, brexucabtagene autoleucel, and its influence on both MCL and indolent lymphomas.
Elacestrant Improves PFS Over SOC in Advanced ER-Positive, HER2-Negative Metastatic Breast Cancer
Elacestrant demonstrates statistically significant and clinically meaningful improvement in progression-free survival for patients with ER–positive, HER2-negative mBC who previously received CDK4/6 inhibition.
Factors Influencing Transplant Eligibility in Patients With MDS
In an interview with Targeted Oncology, Ronald Paquette, MD, discussed MDS and what factors may impact the success of a patient’s treatment when undergoing transplant.
FDA Releases Guidelines for Cancer Clinical Trials, Aligning With Goals of the Biden Administration
The FDA issued 3 final guidances to industry regarding cancer clinical trials that parallel the goals of President Biden's 2016 Cancer Moonshot initiative.
DKN-01 Triplet Shows Encouraging Early Efficacy/Safety in Frontline Gastroesophageal Adenocarcinoma
Findings show DKN-01, tislelizumab, and capecitabine/oxaliplatin (CAPOX) combination to be well tolerated and have encouraging clinical activity as frontline treatment of patients with advanced gastroesophageal adenocarcinoma.
A Look Back at the FDA News from February 2022
Here's a look back at all the FDA happenings from February 2022.
Trimodality Therapy May Be Safer Than Surgery Alone in Urothelial Cancer
In an interview with Targeted Oncology, Sophia Kamran, MD, discussed the effectiveness of trimodality therapy as well as other novel therapeutics in patients with bladder cancer.
MARIPOSA Trial to Examine How Amivantamab Plus Lazertinib Compares With Osimertinib in EGFR+ NSCLC
The MARIPOSA study seeks to assess efficacy, safety, and pharmacokinetics of the combination of amivantamab-vmjw and lazertinib in locally advanced, or metastatic non-small cell lung cancer.
Lack of Guidelines Create Need for Novel Options for Vulvar/Vaginal Melanoma
In an interview with Targeted Oncology, Annelise Wilhite, MD, discussed the findings of a clinical investigation of survival in patients with vulvar/vaginal melanomas.
FDA Approves Pembrolizumab CDx for MSI-H Solid Tumors
The FDA has approved FoundationOne CDx as a companion diagnostic to pembrolizumab for patients with microsatellite instability high solid tumors.
Adagrasib Shows Promise in Treating KRAS G12C-Mutated GI Malignancies
In an interview with Targeted Oncology, Tanios S. Bekaii-Saab, MD, explained how adagrasib works to target KRAS mutations as well as its importance.
BOS172738 Demonstrates Strong Efficacy/Tolerability in RET-Altered MTC and Other Solid Tumors
BOS172738 shows promising results in the treatment of RET gene altered medullary thyroid cancer and non–small cell lung cancer, according to a phase 1 study.
Exploring the Role of Metabolics in Renal Cell Carcinoma
In an interview with Targeted Oncology, Vitaly Margulis, MD, discussed the function and findings of metabolomics in renal cell carcinoma.
Rusfertide Brings Future of Phlebotomies in Polycythemia Vera into Question
Srdan Verstovsek, MD, discussed maintaining hematocrit levels in patients with polycythemia vera as well as research on the use of rusfertide.
Promising Efficacy/Safety Shown With Anlotinib Plus Sintilimab in Endometrial Cancer
A phase 2 trial sought to evaluate the efficacy and safety of the combination of anlotinib and sintilimab in patients with recurrent advanced endometrial cancer.
New Drug Application Accepted For Adagrasib In KRAS G12C-Mutation NSCLC
The FDA has accepted a new drug application for adagrasib for the treatment of patients with non-small cell lung cancer harboring KRAS G12C mutation.
First PSMA PET Set to Improve Imaging in the Prostate Cancer Field
In an interview with Targeted Oncology, Bridget Koontz, MD, United States chief medical officer and deputy global chief medical officer at GenesisCare, discusses 18F-DCFPyL and how the well-tolerated agent can change the way prostate cancer patients are treated
FDA Grants Orphan Drug Designation For CT103A in R/R Myeloma
CT103A is a BCMA-targeted genetically modified autologous T cell immunotherapy that is able to identify and eliminate malignant and normal cells expressing BCMA in R/R Myeloma.
Early Studies Investigate Novel IO Strategy in Merkel Cell Carcinoma and Glioblastoma
Treatment with multiple nucleic acid immunotherapy agents is being evaluated in phase 1/2 clinical trials.
FDA Considers New Drug Application for Poziotinib in HER2 Exon 20-Mutant NSCLC
An application for FDA approval has been submitted for poziotinib as a potential treatment for patients with non–small cell lung cancer harboring HER2 exon 20 insertion mutations.
Positive Results Correlate With Use of Darolutamide in nmCRPC
In an interview with Targeted Oncology, Neal Shore discusses the findings of ARAMIS which looked at darolutamide in men with high-risk non-metastatic castration-resistant prostate cancer, and its primary end point of metastasis-free survival.
2 Clarke Drive Cranbury, NJ 08512